It seems that weight loss will likely be very important for the benefits of the GLP-1 medicines in some conditions, and much less important, or not at all essential, for benefits in other disorders. According to Lane, although GLP-1 receptor agonists show promise in reducing cardiovascular risk factors, long-term cardiovascular safety trials are needed to assess cardiovascular mortality and events
A qualified provider can: Assess baseline health: Bloodwork before starting peptides establishes baseline hormone levels, liver function, kidney function, and other relevant markers
Prioritize protein (30-40g per meal) and fiber-rich foods to naturally stimulate GLP-1, support satiety, and reduce blood sugar fluctuations
The tirzepatide plateau troubleshooting guide covers specific strategies, and the reasons for stalled weight loss on tirzepatide identifies common, fixable causes